Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Plus Rituximab as Front-line Treatment for MALT Lymphoma
NCT06647732Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in mucosa associated lymphoid tissue lymphoma, sponsored by Sun Yat-sen University. Started Oct 2024; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
mucosa associated lymphoid tissue lymphoma
Beyond the preview
Go deeper on NCT06647732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647732.